Bridging academic discovery and industry to accelerate experimental therapeutics, precision medicine, and healthcare technology from bench to clinic
Dedicated to the next generation of physician-scientists
Overview
One flagship center, built to translate science into care
Augusta Experimental Therapeutics Center (AETC) is the flagship innovation platform of Dr Rajpurohit Holdings Group LLC, an innovative biotechnology and life sciences startup established to develop, commercialize, and manage scientific, biomedical, healthcare, and technology-based ventures.
The company serves as the parent organization operating under the flagship of AETC, with a mission to accelerate translational research, therapeutic innovation, precision medicine, and the commercialization of scientific discoveries. It is committed to bridging academic research with industry through novel therapeutic technologies, AI-driven healthcare solutions, drug discovery platforms, biomedical devices, diagnostics, and educational initiatives.
Founded by Dr Surendra Rajpurohit, AETC serves as an integrated platform bringing together multidisciplinary expertise to accelerate the discovery, development, validation, and commercialization of novel therapeutics, diagnostics, and precision-medicine solutions, in collaboration with academia, healthcare institutions, industry partners, government agencies, and entrepreneurs.
To transform scientific discoveries into innovative healthcare solutions through translational research, entrepreneurship, strategic partnerships, and commercialization.
To establish AETC as a globally recognized center of excellence in experimental therapeutics, precision medicine, artificial intelligence, biotechnology, and pharmaceutical innovation, creating technologies that improve healthcare worldwide.
- Experimental Cancer Therapeutics
- Drug Discovery & Development
- Multi-Model Systems in vitro, zebrafish, mouse, multiomic
- Translational Medicine
- Precision Cardio-Oncology
- AI in Healthcare
- Biotechnology & Biomedical Innovation
- Medical Devices & Diagnostics
- Digital Health Technologies
- Research Commercialization & Tech Transfer
- Scientific Consulting & Education
Surendra Rajpurohit PhD
Principal Investigator
He leads the Rajpurohit Lab, where his research applies transparent transgenic zebrafish and mouse models to experimental therapeutics in glioblastoma and cardio-oncology. His work includes the ARQiv platform he developed for high-throughput drug screening, used to screen more than 3,200 drug candidates.
Structure
Twenty-four divisions, organized around one translational pipeline
Every entry below is one of AETC’s 24 operating divisions, numbered as they appear in AETC’s company profile and grouped by the stage of the pipeline they serve: from discovery through clinic to commercialization and training.
Discovery & disease modeling
Experimental Therapeutics Division
HTS Drug Discovery & Development Division
Cancer Research Center
Zebrafish Modeling Laboratory
Tumor Microenvironment Research Laboratory
Cardio-oncology & multi-omics
Fundamental Cardio-Oncology Laboratory
Translational Cardio-Oncology Laboratory
Precision Cardio-Oncology Laboratory
Multi-Omics Genomics & AI Modeling Laboratory
Drug Induced Toxicity Laboratory
Precision medicine, AI & clinical translation
Precision Medicine Division
Artificial Intelligence & Digital Health Division
Biotechnology & Molecular Medicine Division
Translational & Clinical Research Division
Drug Library Division
Biorepository Division
Devices, regenerative medicine & commercialization
Biomedical Innovation & Commercialization Division
Medical Devices & Diagnostics Division
Regenerative Medicine & Cell Therapy Division
Innovative Biotechnology & Life Sciences Division
Education, training & partnerships
Research Education, Training & Scientific Consulting Division
Global Strategic Partnerships & Business Development Division
Mentorship Program for Next Generation Physician Scientists
Dr Rajpurohit Innovation Academy
Programs
Training the next generation of physician-scientists
Division 23
Dr Rajpurohit Mentorship Program
Listed in AETC’s company profile as Division 23. No further program details have been published yet.
Division 24
Dr Rajpurohit Innovation Academy
Listed in AETC’s company profile as Division 24. No further program details have been published yet.
Collaborators & Funding
Building AETC’s portfolio through collaboration and federal research funding
Collaborator
FiteBac Technologies
Alpharetta, Georgia. Listed as a collaborator in AETC’s company profile.
NCI SBIR / STTR
Grant focus areas under pursuit
AETC is preparing an SBIR application to the National Cancer Institute, aligned to NCI’s SBIR/STTR research areas of interest:
- Therapeuticssmall molecules, biologics, radio-modulators, cell-based therapies
- In vitro & in vivo diagnosticscompanion diagnostics, prognostic technologies
- Imaging technologiesagents, devices, image-guided interventions
- Devices for cancer therapyinterventional, surgical, radiation, ablative
- Tools for cancer biology research
- Technologies and agents for cancer prevention
- Technologies for cancer controlbehavioral health interventions, tools for genetic, epidemiologic, behavioral, social, and surveillance cancer research
- Digital healthmobile health, health information technology, bioinformatics